Malfunctioning enzyme may pave way for new MDS treatments

07/10/2013 | Drug Store News

Researchers have discovered a malfunctioning immune system enzyme that can be targeted to eliminate myelodysplastic syndrome-initiating clone cells. "Not only does our research implicate errant immune system signaling in MDS cells, it strongly indicates that inhibiting the function of this hijacked immune pathway may become an effective treatment option for MDS," said lead researcher Daniel Starczynowski. MDS, a blood disorder that precedes leukemia, has few effective therapies and can be cured only through a bone marrow transplant.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA